Key Takeaways
- Margin squeeze from raw materials, not demand collapse: Pigment EBITDA margin fell to ~10% (vs 13–15% average) as crude and natural gas prices rose on war disruption, while agrochemical margins stayed above industry average.
- Volume engine running ahead of value: Agrochemical volumes grew ~40% YoY while value grew ~30%, reflecting 15–20% price declines from peaks as raw material costs ease and customers buy hand-to-mouth.
- The capex cycle is entering its delivery window: Multipurpose plant commissioning by early Q3 FY23, TiO2 Phase 1 by end-Q3/early-Q4 FY23, and Flubendiamide commercial production already started, together targeting ~Rs. 4,500 crore revenue by FY25.
- Management is cautious on near-term visibility: Q1–Q3 are called "challenging" and "not going to be very good," with no surety on maintaining current profitability, though the company expects to stay above industry-average margins annually.
- What to watch next quarter: Whether the multipurpose plant commissions on time in early Q3, any TiO2 technical-resolution progress, and whether pigment margins begin the promised recovery.
Margin & Profitability
- Pigment margin compression: EBITDA margin dropped to ~10% from a 13–15% past-year average because raw material costs rose with crude and natural gas prices driven by the Ukraine conflict, while demand also softened slightly.
- Agrochemical margin resilience: Agrochemical EBITDA margin stayed on the higher side this quarter; management noted the industry average is 16–18% and sometimes they get an advantage to improve on it.
- FOREX tailwind: A Rs. 33 crore foreign-currency gain on receivables, partially offset by a Rs. 7 crore MTM loss on foreign-currency borrowings, produced a net gain of ~Rs. 25 crore that boosted other income. Finance cost was Rs. 9.44 crore, of which only Rs. 2.5 crore was interest because foreign-currency debt carries a ~2% borrowing cost.
- Natural hedge coverage: Exports exceed imports plus foreign-currency loans, covering 55–60% of exposure.
- No inventory gains booked: The company is not in petrochemicals and recorded no inventory gain this quarter.
- Margin philosophy is annual, not quarterly: Management targets better margins than the industry average on an annualized basis, acknowledging it is challenging to keep margins constant when prices drop quarter-to-quarter.
Ankit Patel: "There is no surety whether we will be able to maintain the same profitability. Still, we are optimistic about being above the industry average."
Demand & Pricing Environment
- Export customers buying judiciously: Buyers are purchasing per immediate requirement rather than building volume contracts or inventory, driven by global recession and inflation negativity plus falling raw material prices. Management views this as positive because it prevents heavy inventory buildup at the customer level and sustains continuous small-demand flow.
- Agrochemical price erosion underway: Product prices have come down nearly 15–20% from peak, and if raw material prices continue falling there will be further pressure on selling prices.
- Domestic demand picking up: Monsoon has been good overall, with some patchy impact in UP and Bihar, and demand has started picking up in the domestic market.
- Volume vs value gap: Q1 agrochemical volume grew ~40% YoY while value grew ~30% YoY, implying price decline or mix shift.
- China competition present: No supply constraints from China currently; manufacturing plants are running despite COVID waves, and the company ensures it remains competitive and on par with China.
- Near-term outlook is sober: Management stated Q1, Q2, and Q3 are challenging and "it is not going to be very good," though new expansions, technical capability, and geographic spread will help maintain growth despite price erosion.
Ankit Patel: "It is going to be very difficult in this market condition to predict, but the days are challenging for the first, second, and third quarters for sure... it is not going to be very good."
Agrochemical Growth Drivers
- Synthetic pyrethroids replacing banned chemistries: Organophosphate products like chlorpyrifos are being banned in various countries, and neonicotinoids (imidacloprid, acetamiprid) usage is declining. Synthetic pyrethroids are replacing them and work well in combination with new-chemistry insecticides.
- Flubendiamide market opportunity: Currently imported by MNCs at high prices; domestic manufacturing will lower prices and expand market volume. Current ~300–350 tons of technical imports are expected to double in three years. The company is the first and only Indian firm to get a CIB manufacturing license and has already begun commercial production.
- Backward integration as differentiator: For Lambda-Cyhalothrin and Bifenthrin, the company will be backward integrated and will not buy a single raw material from China, differentiating from other Indian players entering these products.
- Segment mix shifting toward pyrethroids: In Q1, 2,4-D contributed ~20–22% of agrochemical sales, pyrethroids ~60–65%, and organophosphates ~10–12%. The pyrethroids share is expected to increase next year.
- Regulatory moat: Management emphasized that in agrochemicals, manufacturing capability matters but regulatory approvals in various markets are equally vital; without them, you cannot sell the product.
Ankit Patel: "One of the significant factors, synthetic pyrethroids are relatively safe than other insecticides. Organophosphate products like chlorpyrifos are slowly getting banned in various countries... So, these synthetic pyrethroids products will replace them somewhere down the line."
Capacity Expansion & Project Pipeline
Multipurpose Plant
- Commissioning timeline: Expected on stream by early Q3 FY23.
- FY24 revenue expectation: ~Rs. 300–350 crore at ~60% utilisation in the first full year.
- Product profile: Completely different from the existing set, relatively high-value, and manufactured by only one or two companies in India. Realization will be at least better than current products. Capacity will increase by another ~7,000–8,000 tons.
- Advance marketing underway: The company has already begun marketing products including LC Acids and Flubendiamide before plant commissioning to enable 60%+ utilisation in the first year.
Titanium Dioxide
- Phase 1: 16,500-ton capacity, commissioning by end-Q3/beginning-Q4 FY23; full-year operation in FY24.
- Phase 2: Additional 16,500 tons, commissioning in Q3 FY24; full-year operation of both phases (33,000 tons) in FY25.
- FY24 revenue expectation: Rs. 250–300 crore at ~80% utilisation of Phase 1 capacity.
- Grade progression: Will start with Anatase grade and then move to Rutile grade, which has better realization and larger volume applications.
- Technical challenges being addressed: Management acknowledged issues inherited with the plant; the original team that built it is now on board and working to resolve technicalities with help from consultants and technology providers.
- Customer approval timeline: Specialized customers take 3–6 months to approve, but sales can begin earlier to customers with faster approval processes such as smaller paint companies and plastics applications.
- Initial utilisation: Per an analyst's math, the plant will operate at ~50% utilisation of 16,000 metric tons for the first six months; management agreed.
Other Expansions
- Flubendiamide: Commercial production already started; initially targeting the Indian market while export registrations are being worked on for various markets.
- Debottlenecking: A small project enhanced agrochemical capacity by ~1,000 metric tons annually this quarter at minimal cost.
- LC Acid: Already partly commercialized with minimum capacity.
Ankit Patel: "Now we have the people on board with us in the same plant who put up the same old plant, so they know the in and out of it. We have got the same team with us now. So, all the technicalities, whatever issues are there, we are trying to resolve as soon as possible, and it is not that easy, but yes, we are working on it. We are quite hopeful."
Financial Position & Capital Allocation
- Debt raised for expansion: Term loans of Rs. 275 crore finalized in subsidiary Kilburn Chemicals Limited, plus Rs. 150 crore of foreign-currency debt raised in Meghmani Organics Limited at an average rate below 2% p.a. with a 5-year duration. Funds not fully utilised are parked in FD at 5.95%.
- Debt-to-equity expected around 0.5.
- Repayment schedule: FY23: ~Rs. 71 crore; FY24: ~Rs. 90 crore.
- Free cash flow: FY23 free cash flow expected at Rs. 150 crore after CAPEX and debt repayment; operating cash flow will be higher due to operating leverage.
- Dividend policy review: Once projects are commercialized, the dividend payout policy will be reviewed.
- Preference share repayment: Rs. 210 crore of redeemable preference share money from Meghmani Finechem should start flowing back to Meghmani Organics once cash flow eases at Finechem.
- Promoter holding clarification: The apparent decline from 51% to 49.2% is due to Singapore Depository Receipts converting into equity shares and entering the Indian public float; no actual promoter share sale occurred.
Revenue Trajectory & Targets
- Original targets ahead of schedule: Pigment Rs. 1,000 crore and agrochemical Rs. 2,000 crore targets are expected to be achieved before the original FY24 timeline. A new three-year plan is being finalized internally and will be announced publicly.
- FY25 path to ~Rs. 4,500 crore: Multipurpose plant (~Rs. 600–700 crore) plus titanium dioxide (~Rs. 700 crore) plus minor debottlenecks and other CAPEX on existing plants will take revenue from the ~Rs. 2,700 crore trailing level to ~Rs. 4,500 crore by FY25.
- Volume stagnation FY16–FY20 explained: No significant CAPEX for capacity expansion occurred during that period; the company was in a transition phase stabilizing operations and obtaining regulatory approvals for various markets. The formulation plant and 2,4-D plant commissioned in the last year are now driving volume growth.
- 2,4-D utilisation: Running at 70–75%; the plant is high-maintenance-oriented, so when markets are good they run at full capacity and when markets are down they take maintenance shutdowns to capture production when markets recover.
Ankit Patel: "Before three years when we announced this kind of growth plan, people were saying that it was unrealistic and not possible to achieve, but somehow with the support and with God's grace, we have been able to achieve it, and we will revise the future growth plan as well."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Multipurpose plant commissioning | Early Q3 FY23 | Jul–Sep 2022 |
| TiO2 Phase 1 commissioning | End-Q3 / beginning-Q4 FY23 | Dec 2022–Mar 2023 |
| TiO2 Phase 2 commissioning | Q3 FY24 | Oct–Dec 2023 |
| TiO2 Phase 1 FY24 revenue | Rs. 250–300 crore at ~80% utilisation | FY24 |
| Multipurpose plant FY24 revenue | ~Rs. 300–350 crore at ~60% utilisation | FY24 |
| FY25 revenue target | ~Rs. 4,500 crore | FY25 |
| Debt-to-equity | Around 0.5 | Ongoing |
| FY23 free cash flow | Rs. 150 crore after CAPEX and debt repayment | FY23 |
| FY23 debt repayment | ~Rs. 71 crore | FY23 |
| FY24 debt repayment | ~Rs. 90 crore | FY24 |
| Pigment & agrochemical original targets | Rs. 1,000 crore / Rs. 2,000 crore | Before FY24 (ahead of original timeline) |
| New three-year growth plan announcement | Internally being finalized | "Very soon" / "in one or two months" |
| Dividend policy review | After project commercialization | No fixed date |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Revenue | ₹560 cr (agrochemical division) |
| Agrochemical EBITDA margin | 22.5% |
| Pigment EBITDA margin | 10%, improved from 7% in Q4 FY22; past-year average was 13–15% |
| Other income | ₹37.60 cr, includes ₹33 cr FOREX gain and ₹4 cr other interest |
| Finance cost | ₹9.44 cr, of which ₹2.5 cr is interest cost and ₹7 cr is MTM loss on foreign currency loans |
| Net FOREX gain | ₹25 cr (₹33 cr gain on receivables less ₹7 cr MTM loss on borrowings) |
| Agrochemical volume growth | ~40% YoY |
| Agrochemical value growth | ~30% YoY |
| Agrochemical product prices | Down 15–20% from recent peak |
| 2,4-D utilisation | 70–75%, expected to remain at this level for the year |
| Debt-to-equity ratio | 0.46, guidance to remain around 0.5 |
| Long-term gross debt | ₹410 cr; net long-term debt ₹260 cr after ₹150 cr cash not yet drawn |
| Borrowing cost | 2% to 2.5% |
| Dividend payout (FY22) | 12% of PAT, down from 19% in FY21 and 17% in FY20 |
| Promoter holding | 49.2%, down from 51% in Sep 2021 due to SDR conversion into equity, not a sale |